--- title: "Addus HomeCare (ADUS) Q2 Earnings Report Preview: What To Look For" type: "News" locale: "en" url: "https://longbridge.com/en/news/294593945.md" description: "Addus HomeCare (ADUS) reports Q2 earnings after market hours. Last quarter, revenue grew 7.7% YoY to $363.6M, missing estimates but beating EPS. This quarter, analysts expect 7.7% revenue growth, slowing from last year's 21.8%. The company has missed revenue estimates multiple times recently. Peers like BrightSpring and Chemed have reported strong results. ADUS shares are up 9.2% over the past month, trading below the average analyst price target of $133." datetime: "2026-08-02T03:07:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294593945.md) - [en](https://longbridge.com/en/news/294593945.md) - [zh-HK](https://longbridge.com/zh-HK/news/294593945.md) generator: "portal-rs" --- # Addus HomeCare (ADUS) Q2 Earnings Report Preview: What To Look For Home healthcare provider Addus HomeCare will be reporting results this Monday after market hours. Here’s what you need to know. Addus HomeCare missed analysts’ revenue expectations last quarter, reporting revenues of $363.6 million, up 7.7% year on year. It was a slower quarter for the company, with a beat of analysts’ EPS estimates. Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members. This quarter, the market is expecting Addus HomeCare’s revenue to grow 7.7% year on year, slowing from the 21.8% increase it recorded in the same quarter last year. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Addus HomeCare has missed Wall Street’s revenue estimates multiple times over the last two years. Looking at Addus HomeCare’s peers in the senior health, home health & hospice segment, some have already reported their Q2 results, giving us a hint as to what we can expect. BrightSpring Health Services delivered year-on-year revenue growth of 23%, beating analysts’ expectations by 5.9%, and Chemed reported revenues up 8.8%, topping estimates by 1.2%. Chemed traded up 4.2% following the results. Read our full analysis of BrightSpring Health Services’s results here and Chemed’s results here. Investors in the senior health, home health & hospice segment have had steady hands going into earnings, with share prices flat over the last month. Addus HomeCare is up 9.2% during the same time and is heading into earnings with an average analyst price target of $133 (compared to the current share price of $115.48). **ALSO WORTH WATCHING: Nvidia’s Quiet Partner.** Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all. Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. ### Related Stocks - [ADUS.US](https://longbridge.com/en/quote/ADUS.US.md) - [BTSG.US](https://longbridge.com/en/quote/BTSG.US.md) - [CHE.US](https://longbridge.com/en/quote/CHE.US.md) - [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md) - [BTSGU.US](https://longbridge.com/en/quote/BTSGU.US.md) - [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md) ## Related News & Research - [Addus HomeCare COO W. Bradley Bickham files initial beneficial ownership statement](https://longbridge.com/en/news/296143326.md) - [Aurora Investment Counsel Makes New $1.71 Million Investment in Addus HomeCare Corporation $ADUS](https://longbridge.com/en/news/293115434.md) - [Nvidia to use Poolside deal to build alternative to Chinese AI, WSJ says](https://longbridge.com/en/news/296727449.md) - [AMD or Nvidia: Load Up on One AI Chip Stock, but Avoid the Other, Says Investor](https://longbridge.com/en/news/296792383.md) - [Jim Cramer Pushes Back on Nvidia Skeptics Ahead of Earnings — Dan Ives Says Chip Demand Is Crushing Supply 15-To-1](https://longbridge.com/en/news/296793865.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**